Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.
about
Anti-relaxation therapy in GORDTherapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study.Review Article: is Helicobacter pylori relevant in the management of reflux disease?Management of reflux disease.Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitorsExtraoesophageal manifestations of gastro-oesophageal refluxRecent effectiveness of proton pump inhibitors for severe reflux esophagitis: the first multicenter prospective study in JapanRole of duodenogastroesophageal reflux in the pathogenesis of esophageal mucosal injury and gastroesophageal reflux symptoms.Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitisA proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease.Esomeprazole: potent acid suppression in the treatment of acid-related disorders.Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease.The physiological background behind and course of development of the first proton pump inhibitor.Dental erosions and other extra-oesophageal symptoms of gastro-oesophageal reflux disease: Evidence, treatment response and areas of uncertainty.Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.The prescribing of acid suppressants prior to the endoscopic diagnosis of Barrett's oesophagus and oesophagitis.Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression.Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial.A novel prostanoid EP1 receptor antagonist, ONO-8539, reduces acid-induced heartburn symptoms in healthy male volunteers: a randomized clinical trial.An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
P2860
Q28344333-3426F2B0-4894-43EB-9A1D-7ACE51FEBA87Q32182541-D1AC1C0B-8A4B-4A30-A69A-F890CC44B9F3Q34327956-4706E9F2-810E-40EF-BA87-070F7262546BQ34601094-71DE7396-B711-4769-A44A-3DBF8A97F312Q34735634-41C23B74-C132-48C7-9DAE-56B95E41F0CBQ35596016-46C3E7F8-9ECD-4080-804F-74D58EF4AD6DQ36257435-5B9D65F5-0A30-4AE2-8982-5DD655E65D1DQ36265354-9B05DFBF-759E-4134-9C2B-03D260E3628FQ36883336-C17CE424-1F0C-43B8-8CAC-C4E7E7E975F7Q37122451-0C2CE9A5-6B81-44D1-9381-991304EDB654Q37284534-D8E0534B-772D-47CB-B473-6AD65BDF4FD1Q37755220-FCA2EE03-EBB9-4D80-860E-903B77842B8DQ38229080-86F394D9-B56E-47E3-B584-27B1F907F11BQ38413193-12A08280-ED1E-4C4A-955C-5574DEF24A32Q38448498-633C3E24-D3B1-4F54-BACA-C868B06F6FB4Q41560226-81ACD761-24E5-404F-AB99-DE378563062BQ42498100-46EEFBA0-6ABC-4B1F-AADC-E153588FD7DDQ43517064-54C5B820-5C6B-4F70-AFAC-8055E7D5FFEDQ43967099-EFAB6978-22BB-42E0-8F25-344F4BEF2ECBQ45713740-3F73D422-4857-4687-B3DA-D65CB2605EABQ45985042-6E483BA3-1010-40A9-BF2C-C86FBA37A4C3Q46076164-05B44370-06BD-4307-B374-9927D68276DFQ48085570-1BB8CE58-A317-4DF5-A14D-6275571D4A67Q48254878-4BEC5CE0-1609-4E83-AEA0-A6C31A34B010Q50933884-E0271BB5-1D79-460E-9342-59324665E5E2Q51609254-6DCB5356-A08A-4E43-841E-10612CDFC5B2
P2860
Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.
description
1996 nî lūn-bûn
@nan
1996 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Relation between oesophageal a ...... th severe reflux oesophagitis.
@ast
Relation between oesophageal a ...... th severe reflux oesophagitis.
@en
Relation between oesophageal a ...... th severe reflux oesophagitis.
@nl
type
label
Relation between oesophageal a ...... th severe reflux oesophagitis.
@ast
Relation between oesophageal a ...... th severe reflux oesophagitis.
@en
Relation between oesophageal a ...... th severe reflux oesophagitis.
@nl
prefLabel
Relation between oesophageal a ...... th severe reflux oesophagitis.
@ast
Relation between oesophageal a ...... th severe reflux oesophagitis.
@en
Relation between oesophageal a ...... th severe reflux oesophagitis.
@nl
P2093
P2860
P356
P1433
P1476
Relation between oesophageal a ...... th severe reflux oesophagitis.
@en
P2093
Holloway RH
Mackinnon AM
Narielvala F
P2860
P304
P356
10.1136/GUT.38.5.649
P407
P577
1996-05-01T00:00:00Z